Extracellular Vesicle-Derived DNA vs. CfDNA as a Biomarker for the Detection of Colon Cancer
Liquid biopsy has emerged as a promising non-invasive way to diagnose tumor and monitor its progression. Different types of liquid biopsies have different advantages and limitations. In the present research, we compared the use of two types of liquid biopsy, extracellular vesicle-derived DNA (EV-DNA...
Main Authors: | Kavita Thakur, Manu Smriti Singh, Sara Feldstein-Davydova, Victoria Hannes, Dov Hershkovitz, Shlomo Tsuriel |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-07-01
|
Series: | Genes |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4425/12/8/1171 |
Similar Items
-
Using cfDNA and ctDNA as Oncologic Markers: A Path to Clinical Validation
by: Jonathan Dao, et al.
Published: (2023-08-01) -
Can Liquid Biopsy Based on ctDNA/cfDNA Replace Tissue Biopsy for the Precision Treatment of EGFR-Mutated NSCLC?
by: Yi-Ze Li, et al.
Published: (2023-02-01) -
Beyond the Blood: CSF-Derived cfDNA for Diagnosis and Characterization of CNS Tumors
by: Abbye E. McEwen, et al.
Published: (2020-02-01) -
Deep cfDNA fragment end profiling enables cancer detection
by: Yulia V. Zhitnyuk, et al.
Published: (2022-01-01) -
The cfDNA in early cancer detection
by: Hussein Adil Abid, et al.
Published: (2024-01-01)